Among patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, treatment with imlunestrant did not significantly improve progression-free survival (PFS) compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback